Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
Discontinued
Reference number: GID-TA10334
As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
For information, the company have advised it is withdrawing its marketing application from the Medicines and Healthcare products Regulatory Agency (MHRA) and does not intend to commercialize the therapy in the UK. Therefore, in collaboration with the company, NICE has suspended this evaluation from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.